Publications by authors named "C Ill"
Article Synopsis
- Many cancers have mutations in the MAPK pathway that promote cell growth, leading to challenges in treatment with BRAF inhibitors for melanoma and other cancers.
- Some cancer cells can adapt and resume slow proliferation after initial treatment, showing a survival mechanism that is not based on genetic changes.
- The study highlights the role of DNA replication stress and potential therapeutic strategies that target early stress responses to improve the effectiveness of MAPK inhibitors in these cancers.
CDK2 is a core cell-cycle kinase that phosphorylates many substrates to drive progression through the cell cycle. CDK2 is hyperactivated in multiple cancers and is therefore an attractive therapeutic target. Here, we use several CDK2 inhibitors in clinical development to interrogate CDK2 substrate phosphorylation, cell-cycle progression, and drug adaptation in preclinical models.
View Article and Find Full Text PDFArticle Synopsis
- Many cancers with mutations in the MAPK pathway face challenges with drug resistance despite available targeted inhibitors.
- Research shows that certain cancer cells, including those in melanoma, can quickly adapt to treatment by resuming growth after a few days of quiescence.
- This study identifies the Fanconi anemia DNA repair pathway as crucial for these escapee cells' survival, emphasizing the need to target stress tolerance mechanisms for more effective cancer therapies.
Ensuring the safety of therapeutic modalities produced and purified from biological systems is of high concern. Regulatory authorities and the biopharmaceutical industry are continuously seeking to improve methods for the detection, identification, inactivation and removal of potentially contaminating pathogens in biotherapeutic products. Current methods for pathogen detection and identification are designed to discover adventitious as well as known microbial species in product samples.
View Article and Find Full Text PDFPropofol hemisuccinate is a prodrug water soluble form of the lipophilic, phenolic compound propofol (2,6-di-isopropylphenol), that is the active ingredient in the widely used anesthetic agent Diprovan. Propofol binds to GABA(A) receptors but also has a phenolic structure that confers antioxidant properties to the molecule. The effects of propofol hemisuccinate in rat experimental autoimmune encephalomyelitis (EAE) were studied using different doses and time regimes.
View Article and Find Full Text PDF